business
Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study
Abbisko Therapeutics Co., Ltd. (2256.HK) said preliminary results from a Phase II study of lavengratinib (ABSK061) showed improved growth rates in children with achondroplasia, while the investigational therapy continued to demonstrate a favorable safety profile.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
The AI telling farmers when to harvest
BBC Business
Vape prices to rise as new tax takes effect
BBC Business
Energy bills are going up - here's what you can do about it
BBC Business
Flydubai passenger describes putting attacker in chokehold after cockpit stabbing
yahoo.com
FTC opens probe into AI giants including Anthropic and OpenAI
Reuters